. 2023 Apr 3;40(2):197–201. doi: 10.1007/s10585-023-10204-y

Table 2.

Treatment strategy after PSMA staging and biochemical outcomes

Post PSMA treatment	Observation: 22 (21.2%) Prostate bed RT: 50 (48.1%) SBRT to nodal disease: 23 (22.1%) SBRT to Extrapelvic disease: 6 (5.7%) ADT:3 (2.9%)
Post treatment response	PBR: 33 (62.3%) CBR: 29 (54.7%) PSA progression: 5 (9.4%) Stable disease: 15 (28.3%)

Post PSMA treatment

Observation: 22 (21.2%)
Prostate bed RT: 50 (48.1%)
SBRT to nodal disease: 23 (22.1%)
SBRT to Extrapelvic disease: 6 (5.7%)
ADT:3 (2.9%)

Post treatment response

PBR: 33 (62.3%)

CBR: 29 (54.7%)

PSA progression: 5 (9.4%)

Stable disease: 15 (28.3%)

Notes: PBR: partial biochemical response; CBR: complete biochemical response